DCPrime is developing its lead product DCP-001 for the second line treatment of Acute Myeloid Leukemia (AML). Furthermore, the company is developing DCP-002 (DCOne loaded with specific tumor antigens) as an off-the-shelf therapeutic vaccine for the treatment of other types of human cancer.
